COVINA – Calvin Cole likes to refer to StemCyte as “the American Red Cross of stem cells.” Housed in a 40,000-square-foot building at 1589 Industrial Park St. in Covina, StemCyte is one of the most ...
At the core of this milestone is REGENECYTE® (HPC, Cord Blood), which received U.S. FDA Biologics License Application (BLA) approval in late 2024. This designation makes StemCyte the only private cord ...
As we process applications for the 2010 Inc. 500 | 5000, we thought it would be worthwhile to shine a spotlight on some of the companies that are vying to appear on our ranking of the fastest-growing ...
BALDWIN PARK, Calif., Jan. 26, 2026 /PRNewswire/ -- StemCyte, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared an Expanded Access (EA) program for RegeneCyte®, the ...
StemCyte, a leader in regenerative medicine, announced a significant breakthrough in its phase IIa clinical trial of HPC, Cord Blood (HPC, CB) for treating Post-Covid syndrome (Long Covid). This trial ...
This Umbilical Cord Blood Collection Program (UCBCP) is a California statewide program administered by UC Davis Health. The goal of UCBCP is to increase the number of high quality, publicly banked ...
EWING, N.J., May 1 /PRNewswire/ -- StemCyte Inc. today announced that it has located its East Coast operations in Ewing, N.J. The move, which was supported by a Business Employment Incentive Program ...
StemCyte entered an agreement with the UC Davis Umbilical Cord Blood Collection (UCB) Program to advance the collection, processing, and registration of high quality and diverse cord blood cells from ...
StemCyte is one of the world's preeminent cord blood banks and biotherapies companies, and the original "hybrid" company offering both private and public cord blood banking options. StemCyte has long ...
BALDWIN PARK, Calif., Oct. 9, 2018 /PRNewswire/ -- StemCyte, a global regenerative therapeutics company, and Fulgent Genetics (NASDAQ:FLGT), a leading genetic testing company, are proud to announce a ...
The MarketWatch News Department was not involved in the creation of this content. BALDWIN PARK, Calif., Jan. 26, 2026 /PRNewswire/ -- StemCyte, Inc. today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results